NCT06909201

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has not been FDA approved. Its use in this study is investigational.

Detailed description

Primary Objectives: To assess the association between imaging features on longitudinal HP 129Xe MRI and the development and severity of radiation pneumonitis resulting from radiation therapy for non-small cell lung cancer. To determine if HP 129Xe MRI features, in conjunction with a given patient's radiation treatment plan, can predict radiation pneumonitis development and severity. Secondary Objectives: Optimize HP 129Xe MRI acquisition techniques. To determine if HP 129Xe MRI can pre-emptively detect radiation pneumonitis prior to symptom presentation. Compare changes in HP 129Xe MRI metrics to CT-based ventilation metrics over the course of radiation therapy. To identify pulmonary regions more susceptible to radiation damage. To develop alternative radiation treatment plans, based on HP 129Xe MRI features of lung function, that may prevent radiation pneumonitis development and compare to standard-of-care treatment plans.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	HP 129Xe MRI	Gas delivery will be from a Tedlar bag

Timeline

• Start date: 2026-03-31
• Primary completion: 2028-09-01
• Completion: 2030-09-01
• First posted: 2025-04-03
• Last updated: 2026-04-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study